Vaxart, Inc. Operating Lease, Liability, Current
Vaxart, Inc. (VXRT) had Operating Lease, Liability, Current of $2.54 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseLiabilityCurrent · last filed 2026-08-06
- 2026-06-30: Operating Lease, Liability, Current $2.54M.
- 2026-03-31: Operating Lease, Liability, Current $2.53M.
- 2025-12-31: Operating Lease, Liability, Current $2.98M.
- 2025-09-30: Operating Lease, Liability, Current $3.78M.
| Period end | Operating Lease, Liability, Current |
|---|---|
| 2026-06-30 | $2.54M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $2.53M S-1 · filed 2026-05-08 |
| 2025-12-31 | $2.98M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $3.78M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $3.49M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $3.26M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $3.08M S-1 · filed 2026-05-08 |
| 2024-09-30 | $2.88M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $2.87M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $2.80M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $2.70M 10-K · filed 2025-03-20 |
| 2023-09-30 | $2.52M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $2.43M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $2.34M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $2.23M 10-K · filed 2024-03-14 |
| 2022-09-30 | $2.15M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $1.11M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $1.08M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $1.01M 10-K · filed 2023-03-15 |
| 2021-09-30 | $1.34M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $1.79M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $2.01M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $2.05M 10-K · filed 2022-02-24 |
| 2020-09-30 | $1.70M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $804.00K 10-Q · filed 2020-08-06 |
| 2020-03-31 | $855.00K 10-Q · filed 2020-05-12 |
| 2019-12-31 | $841.00K 10-K · filed 2021-02-25 |
| 2019-09-30 | $820.00K 10-Q · filed 2019-11-12 |
| 2019-06-30 | $565.00K 10-Q · filed 2019-08-08 |
| 2019-03-31 | $697.00K 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |